Alexey Danilov, MD, PhD, explains the unmet needs for patients with relapsed/refractory chronic lymphocytic leukemia.
Alexey Danilov, MD, PhD, associate director, Toni Stephenson Lymphoma Center, and professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, explains the unmet needs for patients with relapsed/refractory chronic lymphocytic leukemia (CLL)
In the CLL space, targeted agents such as Bruton tyrosine kinase (BTK) inhibitors, PI3K inhibitors, B-cell lymphoma 2 (BCL2) inhibitors, venetoclax (Venclexta), and more, have come to the forefront.
While targeted therapies have played a role in rapidly expanding the treatment landscape for patients with CLL, a variety of unmet needs remain, including for patients with mutations, high-risk disease, and those who are double refractory.
Transcription:
0:08 | The key unmet needs would include the double refractory patients, those who progressed on BTK, and BCL two inhibitors, as well as patients with high genetic risk disease. Just deletion17p or p53 mutation, those patients still have in furious progression free survival even on novel targeted agents. And if patients who are younger would still be candidates for allogeneic stem cell transplant, we have to do better with that particular patient group.
0:43 | And there is, like I said, a lot of focus on time limited therapy, combination therapy with an effort to achieve deep responses in CLL and longer treatment free periods.
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More